↓ Skip to main content

Dove Medical Press

Article Metrics

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine

Overview of attention for article published in Drug Design, Development and Therapy, June 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)

Mentioned by

patent
2 patents
wikipedia
3 Wikipedia pages
reddit
1 Redditor

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
34 Mendeley
Title
Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
Published in
Drug Design, Development and Therapy, June 2010
DOI 10.2147/dddt.s6627
Pubmed ID
Authors

Bernd Kieseier

Abstract

Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been published. However, benefits need to be weighed against the risks to define the role of these compounds within current treatment regimens. In this review, data on the efficacy of a promising compound, oral cladribine, are discussed and balanced with known and anticipated risks in a postmarketing era, and finally gives an outlook on the potential place of this drug in treatment algorithms for MS in the future.

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 3%
Uruguay 1 3%
Italy 1 3%
Unknown 31 91%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 21%
Other 5 15%
Student > Bachelor 4 12%
Student > Master 4 12%
Student > Postgraduate 3 9%
Other 9 26%
Unknown 2 6%
Readers by discipline Count As %
Medicine and Dentistry 13 38%
Agricultural and Biological Sciences 8 24%
Neuroscience 2 6%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Nursing and Health Professions 1 3%
Other 5 15%
Unknown 4 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 December 2016.
All research outputs
#3,411,758
of 17,351,915 outputs
Outputs from Drug Design, Development and Therapy
#182
of 1,713 outputs
Outputs of similar age
#19,875
of 97,156 outputs
Outputs of similar age from Drug Design, Development and Therapy
#1
of 1 outputs
Altmetric has tracked 17,351,915 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,713 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 97,156 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them